Pharma News
14 Dec 2025 to 20 Dec 2025
Dec 20, 2025
Patent uncertainty: Can China's biotech sector provide support for Big Pharma?
Big Pharma faces a significant "patent cliff" between 2025 and 2030, with an estimated $171 billion in revenue at risk as key drugs lose exclusivity. This shift, compounded by a challenging political landscape and the Biosecure Act, threatens pricing power and market stability. Analysts warn that the industry must quickly innovate to replace aging blockbusters.
Dec 19, 2025
National New Drug Development Foundation Aims for 2030 Target on "Blockbuster Medications
The National New Drug Development Foundation (KDDF) unveiled its 2026 roadmap, aiming to secure approval for over four global innovative drugs by 2030. The initiative includes increased funding for Phase 1 (4.55 billion won) and Phase 2 (9.1 billion won) clinical trials, focusing on AI-driven drug development and enhancing commercialization capabilities for domestic pharma and biotech firms.
Dec 19, 2025
Breakthrough transforms recycling of everyday plastics into cancer-fighting drugs - Phys.org
Researchers at the University of St Andrews have developed a method to convert household PET plastic waste into ethyl-4-hydroxymethyl benzoate (EHMB), a key intermediate for anti-cancer drug Imatinib. This innovative process, utilizing a ruthenium-catalyzed semi-hydrogenation, offers significant environmental benefits over traditional methods, promoting a circular economy in pharmaceutical manufacturing.
Dec 19, 2025
Trump poised to reveal major agreements with pharmaceutical companies aimed at reducing medication costs - WPEC
President Trump announced new agreements with nine pharmaceutical companies, including Merck, Amgen, and Gilead Sciences, to offer discounted prices on flagship drugs as part of his "Most Favored Nation" initiative. The deal aims to reduce prescription costs for Americans, with a collective investment of over $150 billion in domestic manufacturing. The agreements will impact treatments for various chronic conditions.
Dec 19, 2025
Significant effect on healthcare: Trump reveals agreement with major pharmaceutical companies to reduce medication costs.
President Trump announced new agreements with nine major pharmaceutical companies, including Merck, Amgen, and Gilead Sciences, to offer discounted prices on flagship drugs as part of his "Most Favored Nation" initiative. The deals aim to reduce prescription drug costs for Americans, with a collective investment of over $150 billion in domestic manufacturing.
Dec 19, 2025
Anupam Mittal warns India about the dangers of relying on Ozempic for quick weight loss solutions - Storyboard18
Anupam Mittal, founder of People Group, cautioned against the rising use of the diabetes drug Ozempic as a weight loss shortcut in India. He highlighted the potential market growth for GLP-1 drugs, particularly after patent expirations in 2026, while emphasizing the importance of sustainable health practices over quick fixes. Ozempic is currently priced at Rs 8,800 per month.
Dec 19, 2025
Trump poised to reveal major agreements with pharmaceutical companies aimed at reducing medication costs - KEPR
President Trump announced new agreements with nine pharmaceutical companies, including Merck, Amgen, and Gilead Sciences, to offer discounted prices on flagship drugs as part of his "Most Favored Nation" initiative. The deal aims to reduce prescription costs for Americans, with a collective investment of over $150 billion in domestic manufacturing. The agreements will impact treatments for various chronic conditions.
Dec 19, 2025
Trump poised to reveal major agreements with pharmaceutical companies aimed at reducing medication costs - KATU
President Trump announced new agreements with nine major pharmaceutical companies, including Merck, Amgen, and Gilead Sciences, to offer discounted prices on flagship drugs as part of his "Most Favored Nation" initiative. The deals aim to reduce prescription drug costs for Americans, with a collective investment of over $150 billion in domestic manufacturing.
Dec 19, 2025
Significant effect on healthcare: Trump reveals agreements with major pharmaceutical companies to reduce medication prices.
President Trump announced new agreements with nine major pharmaceutical companies, including Merck, Amgen, and Gilead Sciences, to offer discounted prices on flagship drugs as part of his "Most Favored Nation" initiative. The deals aim to reduce prescription drug costs for Americans, with a collective investment of over $150 billion in domestic manufacturing.
Dec 19, 2025
Trump reveals agreement with nine pharmaceutical firms under 'Most Favored Nation' policy to secure... - WION
US President Donald Trump announced new "Most Favored Nation" pricing deals with nine pharmaceutical companies, including Amgen, GSK, and Merck, to lower drug costs. This initiative aims to ensure drugs are sold at the lowest prices available in peer countries, expanding a key aspect of the Trump administration's healthcare agenda.
Dec 19, 2025
Takeda's psoriasis medication developed with AI shows positive results in final phase trials.
Takeda Pharmaceutical announced that its AI-developed experimental pill, zasocitinib, showed promising results in late-stage studies for treating plaque psoriasis, with over half of patients achieving clear skin after 16 weeks. The company plans to file for FDA approval in 2026, aiming for peak annual sales of $3 billion to $6 billion. Zasocitinib could compete with established drugs like Bristol Myers’ Sotyktu and Amgen’s Otezla.
Dec 19, 2025
Cardiac medication sales in Gujarat rise by 11%, according to DrugsControl Media Services.
Sales of cardiovascular disease (CVD) medications in Gujarat surged by 11% year-on-year as of November 2025, attributed to an increase in cardiovascular incidents. This trend highlights a concerning shift in treatment approaches aimed at preventing long-term complications.
Dec 18, 2025
Novo submits application for marketing a new weight-loss medication
Novo Nordisk has submitted a marketing application to the U.S. FDA for CagriSema, a next-generation weight-loss drug expected to be reviewed in 2026. CagriSema combines cagrilintide and semaglutide, the active ingredient in its successful drug Wegovy. However, previous studies showed lower-than-expected weight loss, disappointing investors.
Dec 18, 2025
FDA Assesses Priority Review Vouchers for Merck Medications Amidst Novo Nordisk and Takeda Developments...
The FDA is evaluating priority review vouchers for two Merck drugs, potentially expediting their regulatory process. Meanwhile, Novo Nordisk has submitted an NDA for CagriSema, and Takeda is preparing filings for a psoriasis drug. Additionally, AbbVie and others are nearing a pricing deal with former President Trump, indicating significant activity in the pharmaceutical sector.
Dec 18, 2025
Lilly aims to obtain FDA authorization for its GLP-1 weight loss medication - TechTarget
Eli Lilly's obesity pill, orforglipron, has shown promise in a late-stage study, helping patients maintain weight loss for up to a year after switching from injectable GLP-1 drugs like Zepbound and Wegovy. The drug has been submitted for FDA approval, potentially solidifying Lilly's lead in the weight loss market amid competition from Novo Nordisk's oral Wegovy.
Dec 18, 2025
GSK's Asthma Medication Receives Approval in the U.S.—Could It Become a $4 Billion Success?
GSK has received FDA approval for Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma in patients aged 12 and older. This ultra-long-acting biologic, administered twice a year, has shown a 54% reduction in serious asthma attacks. GSK anticipates a launch between 2026 and 2027, potentially generating up to $3 billion in annual sales, boosting its growth strategy.
Dec 18, 2025
Robert Langer (77), known as the 'Father of Moderna,' the 'Godfather of Deep Tech,' and the 'Edison of Biotechnology' (patent king).
Robert Langer, a renowned MIT professor and co-founder of Moderna, emphasizes the importance of resilience in entrepreneurship, sharing insights from his journey of overcoming initial failures. With over 1,500 patents and 40 startups, he advocates for a culture that celebrates failure and suggests that South Korea should adopt tax incentives to foster innovation in deep tech.
Dec 18, 2025
Germany may be on the verge of making the same mistake with biosimilars as it did with generics | Börsen-Zeitung
Germany's Federal Joint Committee (G-BA) has introduced a new policy on medicine dispensing that the domestic pharmaceutical industry warns could lead to enforced price pressure, risking dependencies and potential supply shortages. This move echoes past mistakes in the healthcare system, raising concerns about the long-term implications for drug availability.
Dec 18, 2025
European Commission Greenlights Incyte's Minjuvi Combination Treatment for Relapsed Cases ... - GeneOnline
The European Commission has approved Incyte’s Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma. This approval enhances treatment options for patients whose disease has returned or failed to respond to previous therapies, marking a significant milestone for Incyte in expanding its oncology portfolio in Europe.
Dec 18, 2025
Japan accelerates reduction of prices for medications with lapsed patents - Nikkei Asia
Japanese officials aim to accelerate the reduction of government-set prices for drugs with expired patents to incentivize pharmaceutical companies to focus on new drug development instead of relying on sales from older medications.
Dec 18, 2025
A Review of the FDA's Patent Timeline for Asthma Inhalers - Petrie-Flom Center
A recent article highlights the challenges asthma patients face in affording albuterol inhalers due to systemic issues in FDA patent listings. The FTC's investigation revealed over 300 improper Orange Book listings, complicating generic competition. Calls for reform suggest a collaborative role for the FDA and the Patent and Trademark Office to address these issues, but significant changes remain unlikely.
Dec 18, 2025
Aribio Obtains New U.S. Patent for AR1001: A Significant Development for Licensing Opportunities...
Aribio announced on December 19 that it received a patent registration from the USPTO for AR1001, its oral Alzheimer's treatment in Phase 3 trials. This recognition strengthens AR1001's exclusivity until 2040, potentially extending to 2043, enhancing its market competitiveness and negotiating power for global partnerships. The company is also pursuing a merger with SorookS, set for February 24, 2026.
Dec 18, 2025
Employers are eliminating coverage for weight loss medications as pharmaceutical companies expand their direct-to-consumer initiatives.
HCA Healthcare will stop covering obesity drugs Zepbound and Wegovy next year, urging employees to purchase them through discount programs from manufacturers Eli Lilly and Novo Nordisk. The decision follows a 90% surge in drug use, raising costs significantly. Experts suggest that these consumer offerings may lead employers to cut coverage, making treatments less affordable for patients.
Dec 18, 2025
FDA Considers National Priority Vouchers for Two Promising Merck Drugs: Report
The FDA is considering granting Commissioner’s National Priority Vouchers to Merck's investigational drugs, enlicitide decanoate and sacituzumab tirumotecan, which could significantly shorten their review periods. Enlicitide decanoate, a cholesterol-lowering pill, showed promising Phase III results, while sacituzumab tirumotecan is being developed for various cancers. Merck anticipates filing for approval in 2024.
Dec 18, 2025
US FDA selects Merck medications with significant sales potential for national priority vouchers.
The U.S. FDA is fast-tracking reviews for two Merck drugs, enlicitide decanoate and sacituzumab tirumotecan (sac-TMT), under its National Priority Voucher program. Enlicitide aims to lower LDL cholesterol and could achieve multibillion-dollar sales, while sac-TMT targets various cancers with potential sales exceeding $10 billion. Merck plans to submit applications for both drugs in 2024.
Dec 18, 2025
Takeda announces success of $4 billion TYK2 medication in extensive psoriasis trials | BioPharma Dive
Takeda's experimental drug, zasocitinib, has shown promising results in two late-stage trials for plaque psoriasis, meeting key objectives against a placebo and Amgen's Otezla. The company plans to seek regulatory approvals in the U.S. and beyond during its 2026 fiscal year. Zasocitinib aims to be a leading oral treatment option for psoriasis, competing in a crowded market.
Dec 17, 2025
The Top High-Yield Pharmaceutical Stock to Invest in with $1,000 Today - The Globe and Mail
Pfizer offers a high 6.6% dividend yield but has a concerning payout ratio over 100% and faces patent expirations. Eli Lilly's dividend yield is only 0.6% with a 30% payout ratio, while Merck presents a balanced option with a 3.4% yield and a 45% payout ratio, making it a safer choice for dividend investors amid patent challenges.
Dec 17, 2025
Pharmaceutical advancements yield positive results - Chinadaily.com.cn
China's pharmaceutical sector is set to exceed $100 billion in cross-border licensing and partnerships by 2025, driven by innovative drug development and a critical supply-demand dynamic. Antibody technologies lead major deals, with oncology as the top target. Novartis AG benefits from improved access to innovative drugs in China, highlighting the country's growing global influence in pharmaceuticals.
Dec 17, 2025
A weight-loss approach that outperforms medications such as Ozempic and Wegovy by five times.
A study from New York University reveals that bariatric surgery, including sleeve gastrectomy and gastric bypass, leads to significantly greater weight loss than GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound). Over two years, surgery patients lost an average of 58 pounds, compared to just 12 pounds for medication users, highlighting surgery's long-term effectiveness.
Dec 17, 2025
GSK Receives FDA Authorization for Innovative Severe Asthma Medication Offering Dosing Benefits
GSK's new asthma drug, Exdensur, has received FDA approval as a maintenance treatment for severe asthma, requiring only two injections per year. This ultra-long-acting antibody targets eosinophils, similar to GSK's existing drug, Nucala. Exdensur aims to reduce asthma exacerbations and improve patient adherence. The drug is expected to launch in the U.S. in early 2026.
Dec 17, 2025
US FDA selects Merck medications with significant sales potential for national priority vouchers.
The FDA is fast-tracking reviews for two Merck drugs: enlicitide decanoate, a cholesterol pill, and sacituzumab tirumotecan (sac-TMT), a cancer therapy. Both drugs are part of the National Priority Voucher program, aiming for expedited reviews. Enlicitide could become the first oral PCSK9 inhibitor, while sac-TMT targets various cancers. Merck anticipates significant sales potential for both.
Dec 17, 2025
Increasing number of lawsuits attribute blindness to GLP-1 medications - Juta MedicalBrief
A federal judicial panel has decided to centralize lawsuits against Novo Nordisk and Eli Lilly, alleging that their weight-loss drugs, including Ozempic, Wegovy, Saxenda, and Trulicity, may cause vision loss. The new multi-district litigation will be held in Philadelphia, separate from existing cases related to gastrointestinal side effects. Currently, there are 30 optic neuropathy lawsuits pending.
Dec 17, 2025
FDA Greenlights Libido-Enhancing Medications for Women After Menopause - OnlyMyHealth
The FDA has approved Addyi, a libido-boosting medication for post-menopausal women, expanding its use to those over 65. Marketed by Sprout Pharmaceuticals, the drug aims to address low sexual desire but may cause side effects like dizziness and nausea. Experts emphasize the importance of personalized care and caution, as the drug is not a universal solution for sexual health issues.
Dec 17, 2025
Promising Pharmaceutical Stocks to Keep an Eye On - December 17th - MarketBeat
Eli Lilly and Company, Pfizer, and AbbVie are highlighted as top pharmaceutical stocks to watch, according to MarketBeat. Eli Lilly offers diabetes and obesity treatments, Pfizer focuses on vaccines and various therapeutic areas, while AbbVie specializes in autoimmune and cancer therapies. These companies have seen significant trading volumes recently, attracting investor attention amid regulatory and clinical trial risks.
Dec 17, 2025
Canada's Pharmaceutical Agency Unveils Updated Resource and Information on Medication Approval and ... - Mondaq
Canada's Drug Agency (CDA-AMC) has released new data revealing a 10% increase in drug submissions and a 15% decrease in approvals for 2024. Oncology drugs represented 32% of submissions. Additionally, HTA submissions rose by 11%, with 93% of recommendations favoring reimbursement under specific conditions. A new resource, "Drug Access in Canada," outlines the drug approval and reimbursement process.
Dec 17, 2025
Novo Nordisk aims to prevent Sun Pharma from launching its weight loss medication.
The Delhi High Court has allowed Sun Pharma to manufacture and export its semaglutide-based weight-loss drug but barred domestic sales until Novo Nordisk's patent expires in March 2026. This ruling follows a similar case involving Dr Reddy’s Laboratories, indicating a trend in India's GLP-1 drug market as companies prepare for a potential launch of generics post-patent expiration.
Dec 16, 2025
Pfizer's concerning outlook indicates significant challenges ahead - Rolling Out
Pfizer has revised its revenue forecasts, expecting $62 billion for 2025, down from previous estimates, due to disappointing COVID-19 product sales and $1.5 billion in patent losses. The 2026 outlook is similarly bleak, with projected earnings per share below analyst expectations. The company is restructuring and pursuing acquisitions, including Metsera, to adapt to a post-pandemic market.
Dec 16, 2025
Lexaria Bioscience Raises $3.5 Million Through Direct Offering to Enhance Research and Development
Lexaria Bioscience Corp. has announced a $3.5 million registered direct offering, selling 2,661,600 shares of common stock to support its research and development and corporate purposes. The company, known for its DehydraTECH technology, aims to enhance drug delivery. Analysts rate LEXX stock as a Buy with a $4.00 price target.
Dec 16, 2025
Intensified Nationwide Efforts Target Illegal Drug Trade in Northern India
Authorities in northern India have intensified operations against the illegal narcotics trade, focusing on codeine-based cough syrups and injectable drugs. This crackdown coincides with an ongoing investigation in Uttar Pradesh into widespread smuggling and sales of these substances.
Dec 16, 2025
Pfizer's subdued forecast for 2026 creates waves in the pharmaceutical industry.
Pfizer Inc. (NYSE: PFE) has projected disappointing financial results for 2026, with revenue and adjusted earnings per share falling below Wall Street expectations. The decline is attributed to reduced demand for COVID-19 products like Comirnaty and Paxlovid, alongside impending patent expirations. The company's stock dropped nearly 4% as it initiates cost-cutting measures and focuses on pipeline investments to regain growth.
Dec 16, 2025
Vertanical's VER-01: Cannabis More Effective than Opioids for Treating Back Pain
German company Vertanical's cannabis drug, VER-01, has shown promising results in trials for chronic low back pain, outperforming opioids in pain relief and sleep improvement without causing opioid-induced constipation. Set to be marketed as Exilby, it could revolutionize pain management in a $3bn market, addressing the significant unmet needs of over 500 million sufferers globally.
Dec 16, 2025
A Possible Candidate for Acquisition in the Weight-Loss Medication Market - Ad-hoc-news.de
Bionxt Solutions is generating acquisition speculation as it develops an oral formulation of semaglutid, the active ingredient in Novo Nordisk and Eli Lilly's blockbuster drugs. With a market cap under €100 million, its proprietary sublingual delivery technology and patent protections make it an attractive target for major pharma firms. However, trading volatility reflects investor uncertainty about its future.
Dec 16, 2025
AbbVie's Upcoming Product Launches: A Look at Their Pipeline - The Globe and Mail
AbbVie (ABBV) is ramping up R&D investments to enhance its pipeline, focusing on immunology, oncology, and neuroscience. Key assets include Rinvoq, tavapadon, and pivekimab sunirine (PVEK), with several nearing FDA review. AbbVie aims for significant label expansions for Rinvoq and has pursued over 30 acquisitions to diversify its portfolio, despite facing competition from Johnson & Johnson and Eli Lilly.
Dec 16, 2025
Eli Lilly vs. Merck: Which Stock is the Better Investment for Investors? - Yahoo Finance
Eli Lilly's retatrutide, a triple-acting incretin, showed significant weight loss and osteoarthritis pain relief in a phase III study. Lilly is expanding its obesity portfolio with orforglipron and plans regulatory filings for it this year. Despite competition from Novo Nordisk's Wegovy, Lilly's Mounjaro and Zepbound are driving strong sales growth, positioning the company favorably in the market.
Dec 16, 2025
AZN and Daiichi's Enhertu Approved by FDA for Initial Treatment of Breast Cancer - Finviz
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received FDA approval for first-line treatment of HER2-positive breast cancer, in combination with Roche’s Perjeta (pertuzumab). This decision follows positive results from the DESTINY-Breast09 study. AstraZeneca will pay Daiichi Sankyo a $150 million milestone. Enhertu is already approved in over 85 countries for various cancer indications.
Dec 16, 2025
Lunit collaborates with Daiichi Sankyo to enhance the development of innovative cancer treatments through artificial intelligence.
Lunit has partnered with Daiichi Sankyo to integrate its AI biomarker platform into the development of two new oncology drug candidates. This collaboration aims to enhance tissue testing accuracy and improve clinical trial efficiency using Lunit SCOPE technologies. Lunit's CEO highlighted this partnership as a significant step in AI-driven drug development, marking a new era in the industry.
Dec 16, 2025
Lawsuits alleging that Ozempic and other GLP-1 medications caused blindness have emerged as the second major mass litigation.
A federal judicial panel has centralized lawsuits against Novo Nordisk and Eli Lilly, alleging that their weight loss drugs, including Ozempic, Wegovy, Saxenda, and Trulicity, may cause vision loss. The cases will be heard in a new multidistrict litigation in Philadelphia, separate from existing lawsuits over gastrointestinal side effects. The companies deny the claims.
Dec 16, 2025
KDDF shifts to rigorous management strategies to create a global hit in the pharmaceutical sector.
The Korea Drug Development Fund (KDDF) announced a strategic shift for its second phase starting in 2026, focusing on performance management and high-potential projects. Goals include creating a global blockbuster drug and securing approvals for four new drugs. Notable 2025 Excellent Projects include Sovargen's RNA therapy and D&D Pharmatech's DD01 for metabolic dysfunction.
Dec 16, 2025
Ipsen finalizes the purchase of ImCheck Therapeutics, enhancing its oncology portfolio.
Ipsen has completed the acquisition of ImCheck Therapeutics, a French biotechnology firm specializing in next-generation immuno-oncology therapies. This strategic move enhances Ipsen's capabilities in oncology, rare diseases, and neuroscience, furthering its commitment to delivering transformative medicines globally. Ipsen is listed on Euronext (IPN) and has a presence in over 100 countries.
Dec 16, 2025
Madras High Court instructs health ministry to establish a committee to assess the safety and effectiveness of pioglitazone and sitagliptin.
The Madras High Court has ordered the Union health ministry to establish a panel of medical experts to review the safety and efficacy of the diabetes medications pioglitazone and sitagliptin. This intervention highlights ongoing concerns regarding these drugs' impact on public health.
Dec 16, 2025
Teva Succumbs to Pressure from the Federal Trade Commission | JD Supra
The Federal Trade Commission (FTC) announced that Teva Pharmaceuticals will remove over 200 improper patent listings from the FDA Orange Book, part of a broader effort to enhance competition and lower drug prices. This decision follows a court ruling that deemed five of Teva's device patents improperly listed. The FTC aims to facilitate access to generic alternatives for asthma, diabetes, and COPD drugs.
Dec 16, 2025
Eli Lilly vs. Merck: Which Stock is the Better Investment for Investors? - Yahoo Finance UK
Eli Lilly's retatrutide, a triple-acting incretin, showed significant weight loss and osteoarthritis pain relief in a phase III study. Lilly is expanding its obesity portfolio with orforglipron and plans regulatory filings for it this year. Despite competition from Novo Nordisk's Wegovy, Lilly's Mounjaro and Zepbound are driving strong sales growth, positioning the company favorably in the market.
Dec 16, 2025
Reasons Behind Today's Decline in Pfizer (PFE) Stock - TradingView
Pfizer (PFE) shares fell 5% after the company revised its 2026 earnings forecast to $2.80-$3.00 per share, below Wall Street's $3.05 estimate. Revenue is projected at $59.5-$62.5 billion, impacted by declining COVID-19 product sales and expiring patents. Pfizer plans to increase research spending and focus on new treatments to drive future growth amid industry challenges.
Dec 16, 2025
Brazil Could Save $600 Million Over Five Years by Producing Generic Versions of Patented AIDS Medications
Brazil is considering breaking patents on three AIDS drugs—Kaletra (Ritonavir/Lopinavir), Efavirenz, and Tenofovir—to reduce costs and improve its successful HIV treatment program. With around 160,000 participants, Brazil aims to save $600 million over five years by producing generics. The country also shares its program and low-cost drugs with several nations, emphasizing solidarity and human rights.
Dec 15, 2025
Argenx struggles to broaden the application of its immune therapy - BioPharma Dive
Argenx has halted the development of its autoimmune drug Vyvgart for thyroid eye disease after two Phase 3 trials showed it was no more effective than a placebo. Despite generating nearly $3 billion in sales this year, Vyvgart has faced setbacks in expanding its use. The company remains focused on other potential indications, including muscle myositis and Sjögren’s syndrome.
Dec 15, 2025
Breakthrough Medication Receives Initial Approval for HER2-Positive Breast Cancer Treatment
The FDA has approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for first-line treatment of unresectable or metastatic HER2-positive breast cancer. This decision follows the DESTINY-Breast09 trial, which showed a 44% reduction in disease progression risk compared to standard treatment. The combination demonstrated an 87% objective response rate, marking a significant advancement in therapy options.
Dec 15, 2025
Odisha set to launch its Pharmaceutical and Medical Devices Policy during the 'Odisha Pharma Summit 2025' event.
The Odisha Government is set to launch the Odisha Pharmaceutical and Medical Devices Policy 2025 at the 'Odisha Pharma Summit 2025'. This initiative aims to attract investments, enhance business operations, and create significant employment opportunities in the life sciences sector.
Dec 15, 2025
Bristol Myers Squibb (BMS): Managing the Patent Expiration Challenge with an Enhanced Pipeline and Strategic Initiatives...
Bristol Myers Squibb (BMS) is navigating a critical phase as it faces significant patent expirations for key drugs like Eliquis and Opdivo. Despite challenges, BMS reported Q3 2025 revenues of $12.2 billion, driven by its Growth Portfolio, which includes products like Reblozyl and Breyanzi. The company is focusing on strategic acquisitions and expanding its pipeline to sustain growth amid impending revenue declines.
Dec 15, 2025
Forecast and Size of the U.S. Generic Pharmaceuticals Market from 2025 to 2033 | Longevity
The U.S. Generic Drugs Market, valued at $95.87 billion in 2024, is projected to reach $131.80 billion by 2033, driven by rising chronic diseases and patent expirations. Key players include Teva Pharmaceuticals, Aurobindo Pharma, and Sun Pharmaceutical Industries. Despite regulatory hurdles and price volatility, generics are essential for affordable healthcare, enhancing access and adherence among patients.
Dec 15, 2025
Delhi Steps Up Efforts Against Illegal and Fake Medications with Extensive Inspections in ...
The Delhi Government's Drugs Control Department has intensified its crackdown on illegal and counterfeit medicines, conducting major inspections in wholesale markets. Coordinated raids with police have led to the seizure of counterfeit products, highlighting the government's commitment to combat the spurious drug trade.
Dec 15, 2025
Eli Lilly Has Exciting Updates for Shareholders - The Globe and Mail
Eli Lilly's weight loss drugs, particularly tirzepatide (Zepbound and Mounjaro), have driven significant revenue growth, with the stock gaining over 30% this year. Recent trials for retatrutide showed an average weight loss of over 28%, marking it as a leading candidate in the weight loss market. Lilly plans to submit orforglipron for regulatory review soon, further enhancing its pipeline.
Dec 15, 2025
Press Announcement: Zoe Lofgren and Ben Cline Unveil Bipartisan Legislation Aimed at Reducing Prescription Drug Prices by ...
Rep. Zoe Lofgren and Rep. Ben Cline have introduced the "Skinny Labels, Big Savings Act," a bipartisan bill aimed at reducing prescription drug costs by enhancing protections for generic manufacturers. The legislation seeks to facilitate faster access to generics and promote competition, addressing the affordability crisis in healthcare. It has received support from patient advocacy groups.
Dec 15, 2025
Rajasthan's FSDA to Introduce Digital Monitoring System for Schedule H1 Drugs to Prevent Abuse
The FSDA Rajasthan will launch a digital tracking system for Schedule H1 medicines to combat illegal sales and misuse. This initiative aims to monitor the distribution of these prescription drugs from manufacturers to patients, enhancing accountability and safety in the pharmaceutical supply chain.
Dec 14, 2025
A groundbreaking approach that extends beyond obesity management is set to be a 'reverse aging' solution...
Kwon Seok-yoon, director of the Korea Institute of Biotechnology, emphasizes the need for a "reverse aging treatment" as a strategic focus for Korea's pharmaceutical research. He highlights the potential of antibody-drug conjugates (ADC) and Life Insurance's 'Nano Body' technology to innovate in bio-products. Kwon aims to elevate Korea's bio research competitiveness to a global level by 2029.
Dec 14, 2025
Ozempic, a weight-loss medication, has been introduced in India with a price tag of INR 8 - Eastern Mirror
Novo Nordisk has launched its weight-loss drug Ozempic in India, priced at INR 8,800 per month. Approved for adults with uncontrolled type 2 diabetes, Ozempic is a once-weekly injectable formulation of semaglutide available in three dosages. The drug aims to improve glycaemic control, support weight management, and reduce cardiovascular and kidney risks associated with diabetes.
Dec 14, 2025
ED Steps Up Action Against Multi-Crore Codeine Cough Syrup Operation
The Enforcement Directorate (ED) has intensified its crackdown on a multi-crore racket involving the illegal trade of codeine-based cough syrups. Following nationwide raids, the ED is investigating a significant money-laundering scheme linked to the diversion of these drugs, revealing a vast network of illicit activities.
Dec 14, 2025
Agra police travel to Puducherry to apprehend three individuals involved in counterfeit drugs, according to DrugsControl Media Services.
Agra police have launched an operation in Puducherry to apprehend three individuals linked to a nationwide counterfeit medicine racket. The initiative aims to combat the manufacture and sale of fake drugs, highlighting the growing concern over the distribution of fraudulent pharmaceuticals across the country.
Dec 14, 2025
A groundbreaking therapy that extends beyond obesity management is set to be a 'reverse aging treatment' that d...
Director Kwon Seok-yoon of the Korea Institute of Bioscience and Biotechnology emphasizes the potential of developing a "reverse aging treatment" that could revolutionize healthcare. He highlights the importance of aging research, including antibody drug complexes (ADC) and Life Insurance's 'Nano Body' technology, to combat diseases linked to aging. Korea aims to enhance its bio research capabilities by 2029.
